- Phase III Trial of PARP Inhibitor Shows First Evidence of Improved Outcomes in Breast Cancer
Memorial Sloan Kettering, ASCO, June 4, 2017
- PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.
Evans Tarra et al. Therapeutic advances in medical oncology 2017 Apr 9(4) 253-267
- Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.
Hollis Robert L et al. OncoTargets and therapy 2017 102539-2551
- The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.
Martinez-Useros Javier et al. BioMed research international 2016 20161869304
- Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
George Angela et al. Nature reviews. Clinical oncology 2016 Dec
sábado, 17 de junio de 2017
PARP - poly(ADP-ribose) polymerase (PARP) [NEW TOPIC PAGE]
From From Genomics & Health Impact Scan Database
This database includes published scientific literature on evidence-based translation of genomic discoveries into improved health care and disease prevention that have a potential impact on population health.